H.R. 2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
CBO Score
$-455,000,000
Documentation
Date of Report
Fri July 22nd, 2022
CBO Report Details
Legislation Details
117th Congress
To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Rep. David Cicilline — D — RI
Prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission to sue in court or institute administrative proceedings to enforce this prohibition. Generally, product-hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this ...
JOIN US!
Sign up below to receive updates when your Members of Congress vote for new spending increases or cuts.
Lost your Password?
Don't be sad- we've got your back. Just enter your email below and instructions on resetting your password will be sent to you.
×